Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma

Not Yet Recruiting

Trial opening soon.

Key information

Conditions

Rhabdomyosarcoma Myosarcoma Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue Neoplasms, Muscle Tissue Sarcoma

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing;
Age ≥ 6 years;
No known effective treatment available or no treatment proven to prolong survival with an acceptable quality of life;
Expected survival time greater than 6 months;
ECOG performance status score of 0-1; -

Exclusion criteria

1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.

Treatment and study plan

mRNA Tumor Vaccine Therapy

Biological

personalized mRNA vaccines

Primary outcomes

Adverse Event

Time frame: From the first administration of the study drug until the occurrence of death, loss to follow-up, withdrawal of informed consent, initiation of a new anti-tumor therapy, or 21 days after the last dose, whichever comes first.

Study contacts

Contact information is provided by the study sponsor or research team.

Xinxin Zhang

CONTACT

[email protected]

+86 15910520109

Sponsors and collaborators

Lead sponsor

Xinxin Zhang

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2028
First posted: Apr 17, 2025
Registry last updated: Apr 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting